Ippen and colleagues assessed the efficacy of GDC-0084, a dual PI3K/AKT pathway inhibitor in breast cancer using in vitro and in vivo models, and the results revealed that GDC-0084 was a potential treatment option, especially for patients with brain metastases 23. Here, AKT1 is linked to breast carcinoma.